LONN Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Lonza Group (SWX: LONN)
›
Lonza Group (SWX: LONN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 20,141 employees.
The shares were at 667.60 CHF on 19 November 2026, up 20.7% over 52 weeks. Its 52-week range is 454.60 CHF to 675.60 CHF: the price is 1.2% below the high and 46.9% above the low.
At a market capitalisation of 46.59B CHF, it trades at 44.2 times trailing earnings and 29.7 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 34.9, a premium of 27% for LONN. It pays a dividend yielding 0.75% (it pays out 32% of its earnings), against a median of 0.74% among the dividend payers in that peer group.
Lonza Group reports return on equity of -3.5%, an operating margin of 23.5% and revenue up 11.2% year over year.
Its debt exceeds its cash by 3.68B CHF, a debt-to-equity ratio of 0.57. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 23 analysts cover the stock, with an average rating of Buy; their mean price target of 719.65 CHF is 7.8% above the current price. The next earnings report is expected on 27 January 2027.